Toronto, Ontario – January 8, 2007 – VisualSonics is pleased to announce that Dr. Bill Clarke has joined its Board of Directors.

Dr. Clarke is the Chief Executive Officer of Cellectar, LLC, a biotechnology company focused on the development of radiopharmaceuticals for the treatment of cancer. Prior to joining Cellectar, Mr. Clarke served as the Executive Vice President, Chief Technology Officer and Chief Medical Officer of GE Healthcare, a provider of medical technologies and services to healthcare providers, from April 2004 to December 2006. In this role, Dr. Clarke was responsible for oversight of the Technology and Medical innovation portfolio of General Electric Healthcare with an annual spend of approximately $1.1 billion US. Additionally, he had oversight of the medical and clinical strategy and policy for GE Healthcare worldwide. Prior to joining GE Healthcare and from December 2000, he was the Executive Vice President, Research & Development, of Amersham Health, a world leader in diagnostic imaging pharmaceutical and radiopharmaceutical development. Dr. Clarke also spent three years at Glaxo Wellcome U.K. as Director of Biological Sciences. He has held a number of academic positions, most recently as Associate Professor at the Departments of Anesthesiology and Critical Care Medicine and Pediatrics at the University of Washington, School of Medicine.

“Bill is a technical visionary and a very experienced architect in the global medical and research imaging field,” says VisualSonics President and CEO Tom Little. “Bill’s experience and insights will make a tremendous contribution to our Board of Directors and to guiding the continued global growth of our company”.

Dr. Clarke joins our two newly appointed members of VisualSonics’ Board of Directors, Dr. Doug Armstrong (Managing Director, Dawson James Securities and Former CEO, Aastrom Biosciences Inc) and Mr. Riccardo Pigliucci (Former Chairman and Chief Executive Officer, Discovery Partners International and Former President and COO, Perkin-Elmer Corporation) and our existing Board of Directors, Jeff Courtney (Partner, VenGrowth Capital Partners Inc), Sam Ifergan (President & CEO, Hargan-Global Ventures), Tom Little (President and CEO, VisualSonics), and Dr. Harold Wodlinger (President, Wodlinger Consulting).

About VisualSonics

VisualSonics is the world’s leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company’s enabling micro-ultrasound technology, the Vevo 770, allows researchers at the world’s most prestigious pharmaceutical and biotechnology companies, hospitals and research centers to conduct genetic research, phenotypic study and drug development.

Micro-ultrasound is the fastest growing preclinical imaging modality. This enabling technology is facilitating research in cardiac and vascular disease, cancer, stem cell research and developmental biology. When compared to other imaging options, only micro-ultrasound has the combination of high-resolution, real-time imaging, in vivo detection and analysis, reasonable cost, ease-of-use, portability and no negative biological effects. More information on VisualSonics can be found at www.visualsonics.com.


Contacts:

Tom Little President & CEO VisualSonics Inc. Toronto, Canada Tel. 416.484.5010 Email tlittle@visualsonics.com